OptimizeRx Co. (OPRX) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $25.88 for the company and are expecting that the company will post $0.03 earnings per share for the current quarter, according to Zacks. Zacks has also assigned OptimizeRx an industry rank of 29 out of 255 based on the ratings given to its competitors.

Several brokerages recently commented on OPRX. Zacks Investment Research downgraded shares of OptimizeRx from a “buy” rating to a “hold” rating in a report on Friday, March 1st. William Blair began coverage on shares of OptimizeRx in a report on Thursday, January 3rd. They set an “outperform” rating on the stock.

Shares of OptimizeRx stock traded up $0.59 during trading hours on Monday, reaching $15.59. The company’s stock had a trading volume of 85,542 shares, compared to its average volume of 56,560. OptimizeRx has a one year low of $2.30 and a one year high of $18.39. The company has a market cap of $183.22 million, a PE ratio of 311.80, a price-to-earnings-growth ratio of 2.69 and a beta of 1.06.

A number of large investors have recently modified their holdings of OPRX. BlackRock Inc. bought a new position in OptimizeRx during the 4th quarter valued at about $55,000. Bank of America Corp DE grew its holdings in OptimizeRx by 15.8% during the 4th quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock valued at $168,000 after purchasing an additional 2,084 shares during the last quarter. Northern Trust Corp grew its holdings in OptimizeRx by 71.5% during the 4th quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock valued at $192,000 after purchasing an additional 7,283 shares during the last quarter. Alambic Investment Management L.P. bought a new position in OptimizeRx during the 4th quarter valued at about $289,000. Finally, Geode Capital Management LLC grew its holdings in OptimizeRx by 294.7% during the 4th quarter. Geode Capital Management LLC now owns 60,861 shares of the company’s stock valued at $667,000 after purchasing an additional 45,440 shares during the last quarter. Institutional investors own 46.25% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Read More: How to invest in a bear market

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.